Format

Send to:

Choose Destination
See comment in PubMed Commons below
Drug Discov Today. 2011 Aug;16(15-16):683-90. doi: 10.1016/j.drudis.2011.05.004. Epub 2011 May 13.

DNA demethylases: a new epigenetic frontier in drug discovery.

Author information

  • 1CellCentric Ltd., Chesterford Research Park, Little Chesterford, CB10 1XL, UK. nessa.carey@cellcentric.com

Abstract

DNA methylation is one of the most extensively studied, and one of the most stable, of all epigenetic modifications. Two drugs that target DNA methyltransferase enzymes are licensed for clinical use in oncology but relatively little attention has focused on the enzymatic pathways by which DNA methylation can be reversed. Recent breakthroughs have identified at least two classes of enzymes that can achieve functional reversal. This review discusses the significance of DNA demethylation in a range of human diseases, the candidate proteins that mediate the demethylation and the opportunities and challenges in targeting these candidates to develop new therapeutics.

Copyright © 2011 Elsevier Ltd. All rights reserved.

PMID:
21601651
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk